A video on Investment Pitch Media explains LOVE Pharma’s plans to continue developing a portfolio of innovative products such as naltrexone, including transdermal drug delivery applications for addiction and long-term COVID.Canadian Business Journal

VANCOUVER, British Columbia, November 7, 2022 (GLOBE NEWSWIRE) — LOVE Pharma (CSE:LUV) (FSE:G1Q0) Continues Plans to Develop a Portfolio of Innovative Products Including Transdermal Drug Delivery Applications doing. On October 11, LOVE Pharma signed a non-binding letter of intent to acquire 100% of Naltrexone Therapeutics. This has resulted in an important IP related to the transdermal delivery of naltrexone, an FDA-approved opioid antagonist. Naltrexone is used primarily to manage alcohol and opioid use disorders by reducing cravings. Euphoria associated with substance abuse disorders.

Media snippets accompanying this announcement are available by clicking the image or link below.

https://ml.globenewswire.com/1.0/snippet/1798/eng#lg=1&slide=0

For more information, watch the InvestmentPitch Media video that provides additional information about this news and the company. You can watch the video at “”.investment pitch“When”Youtube”. If these links are not enabled, please visit the following URLs: www.InvestmentPitch.com Type “Love Pharma” in the search box.

The accessible drug addiction treatment market alone is projected to exceed US$31 billion by 2027. This addition to LOVE Pharma’s portfolio has another potentially promising application: treatment of post-Covid conditions or ‘long COVID’.

As reported by Reuters, following a small number of long-term COVID pilot studies, at least four clinical trials are planned to test naltrexone in hundreds of long-term COVID patients. Additionally, it was reported that naltrexone is on the final list of treatments to be tested in the US National Institutes of Health’s $1 billion RECOVER initiative. In addition to treating symptoms caused by COVID damage to organs, Reuters reported that low-dose naltrexone may actually reverse some of the symptoms that cause the underlying medical condition.

As of November 3, the World Health Organization has confirmed 629 million COVID cases and 6.5 million deaths. Also, according to a National Library of Medicine report, 37.7% of his COVID patients experienced symptoms beyond 12 weeks after infection, leading to a significant market need for treatment.

Management believes this new IP has the potential to extend Love Pharma’s reach into additional therapies and position the company at the forefront of addressing unmet medical needs.

Naltrexone is now available in 50mg form from several generic drug manufacturers. This is 10 times his low dose considered for long-term treatment of COVID, requiring low-dose prescriptions to be filled, limiting access and availability. Transdermal formulations of drugs can be incorporated into patches that are applied to the patient’s skin surface.

As reported, with great promise for early application in the long-term treatment of COVID, transdermal delivery of naltrexone provides drug plasma concentrations with a consistent rate of absorption over the prescribed prescribed time. expected to be possible. Although more research is needed, Naltrexone Therapeutics’ transdermal delivery IP may provide a patient-friendly, low-dose delivery solution that is readily available to patients.

Most importantly, transdermal delivery of naltrexone may eliminate or reduce the side effects of current drugs such as nausea that may limit the growth of the existing naltrexone market.

CEO Zach Stadnyk said:Transdermal delivery provides a convenient, safe, regulated dosage that allows for better bioavailability, stable absorption, ease of use, and reduced gastrointestinal-related side effects common with currently available oral administrations. of naltrexone can be provided to patients. We believe it has the potential to expand the market for naltrexone. ”

Love Pharma’s portfolio also includes a previously announced investment in Starton Therapeutics, which aims to improve the efficacy, make better tolerability and potential uses of approved drugs. It has a proprietary continuous drug delivery technology that can be scaled.

At this time, LOVE Pharma makes no explicit or implied claims that its products have the ability to eliminate, cure or contain Covid-19.

Focused on the global sexual health and wellness market, Love Pharma was founded in 2020 with a mission to bring to market innovative products that enhance sexual health and wellness while improving quality of life. is. Love Pharma holds exclusive licenses to manufacture, package, market and distribute patented therapeutics and pharmaceuticals in Europe, the United Kingdom and North America.

The stock is currently trading at $0.01. For more information, please visit the company’s website. www.love-pharma.complease contact Zach Stadnyk, CEO, by phone at 604-343-2977 or by email. [email protected].

About Investment Pitch Media

InvestmentPitch Media leverages the power of video, combined with extensive distribution including news release services, to put your company’s story ahead of thousands of companies seeking recognition and funding from the financial industry. increase. The company specializes in producing short videos based on important news releases, research reports and other content of interest to investors.

Disclaimer

The information in this Investmentpitch Media Ltd video is for viewer information. Love Pharma paid him no more than $2,000 in cash to produce the current news release in video format. Company information is based on publicly available information. Information provided by Investmentpitch Media Ltd. through its media services shall not be construed as a recommendation, proposal or offer to buy or sell securities, and is provided solely as an information media service. Investmentpitch Media Ltd makes no warranties or promises as to the accuracy or completeness of this information. All due diligence must be done by the viewer or their financial advisor. Investing in securities is speculative and involves risk.

CBJ Newsmaker